Fast Facts: Early Breast Cancer
59 pages
English

Vous pourrez modifier la taille du texte de cet ouvrage

Découvre YouScribe en t'inscrivant gratuitement

Je m'inscris

Fast Facts: Early Breast Cancer , livre ebook

-

Découvre YouScribe en t'inscrivant gratuitement

Je m'inscris
Obtenez un accès à la bibliothèque pour le consulter en ligne
En savoir plus
59 pages
English

Vous pourrez modifier la taille du texte de cet ouvrage

Obtenez un accès à la bibliothèque pour le consulter en ligne
En savoir plus

Description

Written for all members of the multidisciplinary breast cancer care team, and for everyone who wishes to know about breast cancer, this concise resource will aid understanding of the risk of developing breast cancer, the essentials of diagnosis and preoperative assessment, and the current approach to treatment and follow-up, with a focus on how each mode of treatment can be optimized to match the individual patient’s needs based on high-quality evidence. Table of Contents: • Etiopathophysiology and risk • Diagnosis • Staging and clinical status • Locoregional treatment • Adjuvant therapy • Survivorship

Sujets

Informations

Publié par
Date de parution 14 mars 2023
Nombre de lectures 0
EAN13 9783318070026
Langue English
Poids de l'ouvrage 2 Mo

Informations légales : prix de location à la page 0,0005€. Cette information est donnée uniquement à titre indicatif conformément à la législation en vigueur.

Extrait

Fast Facts: Early Breast Cancer
First published 2017
Second edition 2023
Text 2023 Jayant S Vaidya, Vivek Patkar
2023 in this edition S. Karger Publishers Ltd
S. Karger Publishers Ltd, Merchant House, 5 East St. Helen Street, Abingdon,
Oxford OX14 5EG, UK
Book orders can be placed by telephone or email, or via the website.
Please telephone +41 61 306 1440 or email orders@karger.com
To order via the website, please go to karger.com
Fast Facts is a trademark of S. Karger Publishers Ltd.
All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the express permission of the publisher.
The rights of Jayant S Vaidya and Vivek Patkar to be identified as the authors of this work have been asserted in accordance with the Copyright, Designs Patents Act 1988 Sections 77 and 78.
The publisher and the authors have made every effort to ensure the accuracy of this book but cannot accept responsibility for any errors or omissions. For all drugs, please consult the product labeling approved in your country for prescribing information.
Registered names, trademarks, etc. used in this book, even when not marked as such, are not to be considered unprotected by law.
A CIP catalogue record for this title is available from the British Library.
ISBN 978-3-318-07021-7
Vaidya JS (Jayant)
Fast Facts: Early Breast Cancer/
Jayant S Vaidya, Vivek Patkar
The authors wish to thank Professor David Joseph, Dr Alison Jones, Professor Michael Baum and Professor Harvey Schipper for their contributions to previous editions of
Fast Facts: Breast Cancer from which some of this text is adapted: Vaidya JS, Joseph D.
Fast Facts: Breast Cancer, 5th edn. Oxford: S. Karger Publishers Ltd, 2014.
Medical illustrations by Dee McLean, London, and Anna-Maria Dutto, Withernsea, UK.
Typesetting by Amnet, Chennai, India.
Printed in the UK with Xpedient Print.
List of abbreviations
Introduction
Etiopathophysiology and risk
Diagnosis
Staging and clinical status
Locoregional treatment
Adjuvant therapy
Survivorship
Useful resources
Index
List of abbreviations
AI: aromatase inhibitor
ALND: axillary lymph node dissection
CMF: cyclophosphamide, methotrexate and 5-fluorouracil
CT: computed tomography
DCIS: ductal carcinoma in situ
DFS: disease-free survival
DIEP: deep inferior epigastric artery perforator
DNA: deoxyribonucleic acid
EBRT: external beam radiotherapy
ER : estrogen receptor (positive/negative)
FNAC: fine-needle aspiration cytology
GnRH: gonadotropin-releasing hormone
HER2( ): human epidermal growth factor 2
HR( ): hormone receptor (positive/negative); this term encompasses both ER and PgR
HRT: hormone replacement therapy
IHC: immunohistochemistry
LCIS: lobular carcinoma in situ
LILAC: Life and Longevity After Cancer study
MRI: magnetic resonance imaging
mTOR: mammalian target of rapamycin
OS: overall survival
OST: ovarian suppression therapy
PARP: poly-adenosine diphosphate (ADP) ribose polymerase
pCR: pathological complete response
PD-L1: programmed cell death ligand 1
PET: positron emission tomography
PFS: progression-free survival
PgR( ): progesterone receptor (positive/negative)
RCT: randomized controlled trial
RFS: recurrence-free survival
RNA: ribonucleic acid
SLN: sentinel lymph node
TARGIT-IORT: targeted intraoperative radiotherapy
TNBC: triple-negative breast cancer
TNM: tumor-nodes-metastases
VMS: vasomotor symptoms
WBRT: whole-breast radiotherapy
WLE: wide local excision
Introduction
Over the last few decades, we have seen great improvements in our understanding and treatment of breast cancer. Breast cancer has dropped to seventh place on the list of leading causes of death in women worldwide. Such improved survival (from 60% to 90%) has meant that, in the last two decades, there has been increased focus on improving quality of life and minimizing overtreatment. A balanced view of the risks, harms and benefits of any intervention, from screening and diagnosis to the treatment of cancer, is gaining importance.
In this new edition, we outline the importance of triple assessment (clinical examination, imaging and pathology) for a confident diagnosis, including methods of eliciting subtle signs of early cancer such as dimpling ( Figure 0.1 ). We also review key practice-changing evidence in surgery, radiotherapy and systemic therapy.
Advances in technology have made it possible to speed up treatment delivery and minimize side effects without compromising effectiveness. Some of these advances, such as intraoperative radiotherapy, have offered pragmatic solutions to new challenges posed by the recent coronavirus pandemic.

Figure 0.1 Dimpling of skin, seen just above the left nipple here, is a subtle sign of early breast cancer that can be easily missed if one does not look for it. (a) Asking the patient to raise their arms or bend forwards, and (b) examining the breast under good lighting can help to ensure these signs are not missed (see Clinical examination, pages 30-32 for more details).

Figure 0.2 Targeted intraoperative radiotherapy (TARGIT-IORT) is delivered immediately after wide local excision (lumpectomy) surgery for breast cancer (see page 55 for more details).
Following the approach of better targeted surgery, radiotherapy has moved from whole-breast irradiation to targeted radiotherapy ( Figure 0.2 ). Biological/antibody therapy and modulation of the tumor microenvironment is now included as part of systemic therapy in addition to chemotherapy and endocrine therapy. Meanwhile, immunotherapy and targeted treatments such as poly-adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitors have shown promise in triple-negative breast cancer.
The recent surge in artificial intelligence and deep learning capabilities, though in its early days, shows promise of improving the accuracy and speed of diagnosis, aiding clinical decision-making and leading to better outcomes.
Written for all members of the multidisciplinary breast cancer care team, and for everyone who wishes to know about breast cancer, this concise resource will aid understanding of the risk of developing breast cancer, the essentials of diagnosis and preoperative assessment, and the current approach to treatment and follow-up, with a focus on how each mode of treatment can be optimized to match the individual patient s needs based on high-quality evidence.
1 Etiopathophysiology and risk
Definitions
Early breast cancer refers to cancer that has not spread beyond the breast or the axillary lymph nodes. This includes ductal carcinoma in situ (stage 0) and stage I, IIA, IIB and IIIA invasive breast cancers (see Staging, Chapter 3 ). The term invasive is unique to breast cancer: in no other cancer is such tautology used. It simply means that cancer cells have crossed the basement membrane of the duct and can potentially spread. It is only used because of the popularity of the terms ductal or lobular carcinoma in situ (DCIS and LCIS) in which cancer cells have not crossed the basement membrane; such lesions, if pure, are theoretically not a risk to life. DCIS and LCIS are usually identified by mammographic screening or as a chance finding after biopsy of a benign lesion. Ductal intraepithelial neoplasia would be the preferred name and would remove the unnecessary taboo of cancer when these lesions are diagnosed.
There are no histopathological or molecular markers to accurately predict the progression from DCIS to invasive disease with certainty. Those that are palpable, show comedo necrosis and have higher expression of p16, cyclooxygenase-2 (COX-2) and Ki67, have increased risk. The risk of invasive cancer is believed to increase nine- to elevenfold in a woman in whom DCIS is treated only by removal of the affected area. 1
Incidence and mortality
Worldwide, breast cancer is the most common form of cancer among women, with an estimated 2.26 million new cases diagnosed in 2020. 2 Although mortality has declined in most areas since 1990, 2 , 3 it is estimated that around 685 000 women worldwide died from breast cancer in 2020, with mortality varying between countries. 2 However, breast cancer is not the leading cause of death in women; in England, dementia and Alzheimer disease, heart disease, stroke, pneumonia and flu, and lung cancer are higher up the list. 4 These changing trends in mortality, together with the fact that breast cancer treatments have been linked to a decline in cognitive function, 5 , 6 have many implications for women when they are making decisions about stopping hormone replacement therapy (HRT) or taking chemotherapy, radiotherapy or endocrine therapy for modest cancer survival benefits.
Structure of the breast and surrounding tissues
The breast is composed of glandular and adipose tissue in varying proportions. The glandular tissue consists of 15-20 lobes containing numerous lobules that are linked by ductules ( Figure 1.1 ). The ductules combine to form the lactiferous ducts, which open into the lactiferous sinuses and empty through the nipple. The breast is enclosed in two layers of fibrous tissue connected by Cooper s ligaments, which give it its characteristic shape. Invasion of Cooper s ligaments by cancer shortens the ligaments, leading to the classic early sign of dimpling of the skin when the patient stands with their hands on their hips, contracting the pectoralis. Dimpling is also enhanced when the patient has their arms raised (see Figure 0.1 , page 7) or when they bend forwards.
Pathophysiology
Most breast cancers are epithelial tumors, arising from either the milk-producing glands (lobular carcinomas) or, more commonly, the draining ducts (ductal carcinomas); only a small number are non-epithelial, involving the stroma or soft tissues.

Figure 1.1 Structu

  • Univers Univers
  • Ebooks Ebooks
  • Livres audio Livres audio
  • Presse Presse
  • Podcasts Podcasts
  • BD BD
  • Documents Documents